English
Structure via PubChem · Public domain (PubChem)
carisbamate
Sign in to saveAlso known as RWJ-333369, (S)-carisbamate, YKP-509, Comfyde
Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug that was under development by Johnson & Johnson Pharmaceutical Research and Development but never marketed.
Chemical data
- Formula
- C9H10ClNO3
- Molecular weight
- 215.63 g/mol
- IUPAC name
- [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate
- SMILES
- C1=CC=C(C(=C1)[C@@H](COC(=O)N)O)Cl
- InChIKey
- OLBWFRRUHYQABZ-MRVPVSSYSA-N
- XLogP
- 1
- Polar surface area
- 72.6 Ų
- H-bond donors
- 2
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 215.03492086
Show 3 more facts
- isomeric SMILES
- C1=CC=C(C(=C1)[C@@H](COC(=O)N)O)Cl
- chemical formula
- C₉H₁₀ClNO₃
- canonical SMILES
- NC(=O)OCC(O)c1ccccc1Cl
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
3 sectionsContents
- Clinical study
- History
- References
Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug that was under development by Johnson & Johnson Pharmaceutical Research and Development but never marketed.
==Clinical study== A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown.
Excerpted from Wikipedia’s “carisbamate” article, available under the CC BY-SA 4.0 licence.